Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Merger or Acquisition (October 2025)
23 slides from Halozyme Therapeutics's merger presentation, Oct 1, 2025
Slide 1: Halozyme to Acquire Elektrofi
Halozyme to Acquire Elektrofi Investor Conference Call NASDAQ: HALO October 1, 2025 1
Slide 2: Forward Looking Statements
Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements termination of the patent terms for the combined group’s drug delivery technologies, unexpected levels of including, without limitation, statements conce
Slide 3: Agenda
Agenda Transaction Summary Expanding Offerings in Innovative Drug Delivery Technology Hypercon Technology Strengthening Long-Term Growth Q&A 3
Slide 4: Transaction Summary
Prrcrcxyme Transaction Summary
Slide 5: Compelling Transaction Rationale
Compelling Transaction Rationale Strong Strategic Fit Extends Halozyme’s vision and breadth of innovative drug delivery technologies by adding 1 Hypercon , an innovative, first mover, differentiated drug delivery technology that uniquely achieves biologic concentration as much as 4-5X higher than to
Slide 6: Compelling Transaction Rationale: Poised for Growth
Compelling Transaction Rationale Poised for Growth Near-term inflection and value creation with two partners projected to begin 1 HyperconTM formulated product clinical development for de-risked MoAs that are approved blockbuster products by year end 2026, or earlier 1 Clear pathway for significant
Slide 7: Transaction Overview
Transaction Overview • $750 million upfront payment • $150 million in future contingent milestone payments Consideration • Three separate $50 million payments upon successful marketing approval of the first three Hypercon products • Transaction financed by Halozyme’s existing cash on balance sheet a
Slide 8: Expanding Offerings in Innovative Drug Delivery Technology
Expanding Offerings in Innovative Drug Delivery Technology 8
Slide 9: Extends Halozyme's Vision and Broadens Offerings in Drug Delivery
Extends Halozyme’s Vision and Broadens Offerings in Drug Delivery De te ve va l o op Inn Today Our Vision Many breakthrough Breakthrough therapies require therapies will the patient’s life to fit the patient’s life fit the treatment Pa tn se r er e n Lic 9
Slide 10: Broad Portfolio of First-to-Market Proprietary Technologies
Broad Portfolio of First-to-Market Proprietary Technologies Setting new standards in convenience, accessibility, and treatment options ENHANZE® Hypercon First commercialized and scaled proprietary technology that Advanced, proprietary microparticle technology that unlocks enables rapid, SC delivery
Slide 11: Expanding the Potential Number of Product Opportunities
Expanding the Potential Number of Product Opportunities GROWTH DRIVERS ENHANZE® Hypercon + ENHANZE® First Major Region Approvals Illustrative Projections Number of products 2013 - 2025 2026 - 2035 becoming available in volume/dose making auto-injector and at- home delivery, a reality Number of SC bi
Slide 12: Well-Aligned, Licensing and Recurring Revenue Business Model
Well-Aligned, Licensing and Recurring Revenue Business Model Royalty-led business Collaboration revenue Milestone revenue Royalty revenue Partner support No clinical study / commercial costs Advisory role supporting partners Highly efficient and leverageable No manufacturing plant ownership 12
Slide 13: Multiple Valuable Hypercon Partnerships Already Established for Up to 12 Targets
Multiple Valuable Hypercon Partnerships Already Established for Up to 12 Targets, With Opportunity for Continued Expansion • 1 target and up to 1 additional target • Transaction Terms: • Upfront payment and future milestones across both targets • Mid-single digit royalties • Agreement signed April 2
Slide 14: Hypercon Technology
Prrcrcxyme Hypercon™ Technology
Slide 15: Introduction to Elektrofi
Introduction to Elektrofi Formulating the Future of Biologics Mission & Vision Leadership Business Overview Chase Coffman, Co-Founder & CEO Founded in Elektrofi has been reimagining the delivery of life saving and life His extensive background in fluid mechanics and microsystems helped form the foun
Slide 16: Resolves Formulation and Volume Delivery Limitations of IV Biologic Therapies
Resolves Formulation and Volume Delivery Limitations of IV Biologic Therapies Hypercon Traditional Microparticle Ultra High Naturally Rehydrates Biologic Protein Formation Concentration Upon Contact with SC Space 40 – 180 400 – 500 mg / mL mg / mL 16
Slide 17: Elektrofi Partnering Model: Optimized Approach Applied
Elektrofi Partnering Model: Optimized Approach Applied Optimize Execute Small Support Manufacture Market, Sell Process for Scale Technology Product at and Partner- Manufacturing Transfer to Commercial Distribute Specific for Partner Scale Product Biologic Optimization Elektrofi Services Provided Par
Slide 18: Hypercon Long Duration IP into 2040s Supports Long Term Revenue Growth
Hypercon Long Duration IP into 2040s Supports Halozyme’s Long Term Revenue Growth Opportunity Granted Pending U.S. Pending Foreign Lengthy Patent U.S. Patents Applications Applications Term Remaining Numerous Patent protection 9 patents across 19 applications extends well into applications 6 distinc
Slide 19: Strengthening Long-Term Growth
Strengthening Long-Term Growth 19
Slide 20: Poised for Growth
Poised for Growth Two partners projected to begin Hypercon formulated product clinical development within the next 12-15 months, or earlier • Initial collaboration products include de-risked MoAs, that are approved blockbusters today Defining registration paradigm for Hypercon that makes clinical de
Slide 21: Halozyme Capabilities De-Risks and Accelerates Elektrofi's Commercialization
Halozyme Capabilities De-Risks and Accelerates Elektrofi’s Commercialization • Supports advancement of technology’s recognition by regulators Deep CMC Expertise • Skilled in meeting CMS requirements and resolving CMC questions Regulatory and • Deep understanding of global regulatory requirements and
Slide 22: Q&A
Prrcrcxyme Qk&A
Slide 23: Halozyme Reaffirming 2025 Financial Guidance
Halozyme Reaffirming 2025 Financial Guidance1 2025 Guidance • 26-33% YOY growth • Milestones for the remainder of the year are expected to be Total Revenue $1,275 - $1,355M • weighted in the fourth quarter Product sales for the remainder of the year are expected to be weighted in the fourth quarter,
Halozyme Therapeutics — Merger or Acquisition (October 2025) on 6ix